Corvidia Therapeutics to Present on Novel Anti-Inflammatory Therapy for Cardio-Renal Disease at J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 4, 2019 /PRNewswire/ -- Corvidia Therapeutics Inc., a leading clinical stage biotechnology company, will present its work on an investigational cardio-renal therapy being developed to address residual inflammatory cardiovascular risk in patients living with Chronic Kidney Disease (CKD) at the 37^th Annual J.P. Morgan Healthcare Conference in San Francisco next week. 

Chief Executive Officer Marc de Garidel will share details on Corvidia's multi-scale approach utilizing genomic, phenomic and interventional evidence in the development of precision medicines for cardio-renal patients. Corvidia's lead asset, ziltivekimab, is an anti-inflammatory monoclonal antibody targeting a patient population genetically-susceptible to the effects of a specific type of inflammation.

Inflammation has been established as a causal factor in the residual risk of cardiovascular patients, particularly within the context of chronic kidney disease, with a susceptible population of over a million patients worldwide. Corvidia is developing evidence for Interkleukin-6 as a factor in this inflammatory cardiovascular risk in patients with CKD who carry both genetic and clinical risk characteristics. Mr. de Garidel will offer insight into how Corvidia Therapeutics is utilizing a combination of genomics and patient risk factor analysis to develop its lead asset for patients living with CKD.

Presentation Details 

DATE: Thursday, January 10, 2019

TIME: 10:30 am PST

LOCATION: Elizabethan D, Westin St. Francis Hotel, San Francisco

About Corvidia Therapeutics Inc.
Corvidia Therapeutics Inc. is a clinical stage biotechnology company based in Waltham, Massachusetts pioneering the next generation of cardio-renal therapies. Corvidia's pipeline programs utilize functional genomics to identify patients with sensitivity to specific biologic pathways, allowing for efficient development and path-to-market for drugs targeting those pathways. Among our portfolio of innovative therapeutic candidates, we presently have an experimental therapy in Phase 2 development for a genetically-defined patient population with chronic kidney disease. Corvidia's other preclinical programs are in various stages of pre-clinical development and are focused on cardiovascular diseases. For more information, please visit www.corvidiatx.com

Press Inquiries:

McDougall Communications on behalf of Corvidia Therapeutics Inc. 
Contact: Elizabeth Harness, [email protected], Tel: +1 (585) 435 -7379

SOURCE Corvidia Therapeutics Inc.

Related Links

http://corvidiatx.com